ArticleAntimicrobial agents and chemotherapy2005
High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Trial
- Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.BMC infectious diseases · 2017Trial
- The impact of fluoroquinolone-resistant enterobacterales colonization on fluoroquinolone prophylaxis efficacy in hematopoietic cell transplant recipients.BMC infectious diseases · 2025Article
- Ultrasound-Assisted Extraction: Unlocking the Antibacterial Potential ofMolecules (Basel, Switzerland) · 2025Article
- Global burden of urinary tract infections in older women from 1990 to 2021 with projections to 2040: a trend analysis of the Global Burden of Disease Study 2021.Frontiers in cellular and infection microbiology · 2025Article
- Effectiveness of selective antibiotics use in ESBL-related UTIs.BMC microbiology · 2024Article
- CTX-M, TEM, and SHV Genes inInfection and drug resistance · 2024Article
- Extended-Spectrum β-Lactamase-ProducingRisk management and healthcare policy · 2024Article
- Urinary tract infections in older adults: associated factors for extended-spectrum beta-lactamase production.Frontiers in microbiology · 2024Article
- Antimicrobial resistance profiles of salmonella spp. and escherichia coli isolated from fresh nile tilapia (oreochromis niloticus) fish marketed for human consumption.BMC microbiology · 2023Article
- Transferable IncX3 plasmid harboring blaMolecular biology reports · 2023Article
- Article
- A spectrum of non-spore-forming fermentative and non-fermentative Gram-negative bacteria: multi-drug resistance, extended-spectrum beta-lactamase, and carbapenemase production.Frontiers in antibiotics · 2023Article
- Extended-Spectrum Beta-Lactamases ProducingAntibiotics (Basel, Switzerland) · 2022Review
- Sink survey to investigate multidrug resistance pattern of common foodborne bacteria from wholesale chicken markets in Dhaka city of Bangladesh.Scientific reports · 2022Article
- High Prevalence of Multi-Drug Resistance and Extended-Spectrum Beta-Lactamase-ProducingInfection and drug resistance · 2022Article
- The magnitude of extended-spectrum beta-lactamase- producingAccess microbiology · 2021Review
- Antimicrobial Resistance Profiling and Molecular Epidemiological Analysis of Extended Spectrum β-Lactamases Produced by Extraintestinal InvasiveFrontiers in microbiology · 2021Article
- Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.Pathogens (Basel, Switzerland) · 2020Review
- Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance.eLife · 2020Observational
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the susceptibility of 312 extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae isolates with that of 1,216 ESBL nonproducers. Of ESBL producers, 25% were susceptible to gentamicin, 30% to trimethoprim-sulfamethoxazole, 41% to ciprofloxacin, and 60% to piperacillin-tazobactam. ESBL nonproducers were more often susceptible to these agents. ESBL-producing Enterobacteriaceae represent a major source of resistance to various antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.